Status:

UNKNOWN

Triple Negative Breast Cancer: Study of Molecular and Genetic Factors

Lead Sponsor:

Institut Paoli-Calmettes

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

Breast cancer triples negatives (TN; 15 % of the cases) are characterized by a high histoprognostic grade, a strong proliferation, a strong metastatic power, and a worse prognosis than the other forms...

Eligibility Criteria

Inclusion

  • women \> 18
  • non metastatic breast cancer
  • triple negative
  • 5 years follow-up
  • signed informed consent

Exclusion

  • other cancer (except in situ)
  • metastases at diagnosis
  • impossibility of follow-up

Key Trial Info

Start Date :

March 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2020

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT01434420

Start Date

March 1 2011

End Date

March 1 2020

Last Update

December 31 2014

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Centre jean Perrin

Clermont-Ferrand, France, 63011

2

Hopital La Timone

Marseille, France, 13005

3

Institut Paoli-Calmettes

Marseille, France, 13009

4

Centre Antoine Lacassagne

Nice, France, 06189

Triple Negative Breast Cancer: Study of Molecular and Genetic Factors | DecenTrialz